糖尿病被列为世界第三大疾病,其中2型糖尿病患者占全部糖尿病人群中的90%以上，而胰岛素抵抗是2型糖尿病的普遍现象。改善胰岛素抵抗成为研究热点。.课题组在体研究发现且国外体外研究表明,存在于一些治疗糖尿病的植物及资源丰富的民族药材中的羽扇豆酮,在改善2型糖尿病胰岛素抵抗方面有发展成为新药的潜力。但羽扇豆酮改善胰岛素抵抗的效果及其机制和体内作用物质还需进一步探明。因此，本项目拟通过高糖高脂结合小剂量链脲佐菌素致2 型糖尿病大鼠胰岛素抵抗模型，结合运用现代分子生物学及分析化学的研究方法，进行以下研究：①评价羽扇豆酮对2 型糖尿病大鼠胰岛素抵抗的改善作用②羽扇豆酮治疗后GLUT-4、IRS-1/-2、PPAR-γ及InsR基因和蛋白表达的变化③推导和鉴定羽扇豆酮改善2 型糖尿病大鼠胰岛素抵抗的体内作用物质。这利于推动羽扇豆酮及早应用于临床或将其作为先导化合物进一步开发利用，具有十分重要的科学意义。

Diabetes was listed as the world's third largest disease, in which more than 90% was type 2 diabetic. As a common phenomenon in the course of type 2 diabetes, insulin resistance is considered to be related to the pathogenesis of it. Improving insulin resistance become a research hotspot..Foreign research in vitro and our study in vivo all show that in some plants which have the treatment of diabetes exists lupenone and the resource-rich national medicinal materials' chemical constituents also contain lupenone.lupenone may have the potential to be applied into new drugs to treat diabetes and improve insulin resistance.But the lupenone's efficacy and mechanism of insulin resistance and the target in vivo need to be further proven. Therefore, we plan to establish rats model of type 2 diabetes with insulin resistance (rats were fed with high glucose and high fat diet, then injection with a small dose streptozotocin to induce insulin resistance), modern molecular biology and analytical chemistry methods were combined for the following researches: ① Evaluation the efficacy of lupenone for improve type 2 diabetes rats'insulin resistance.② Detecting GLUT-4,IRS-1,PPAR-γ?and InsR expression changes after treatment.③ Derivation and identification the target that lupenone improve type 2 diabetes rats' insulin resistance in vivo. Those researches have important scientific significance, for promoting lupenone is used in clinical earlier or as lead compound for further development and utilization.